BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su Y, Ng K, Yu M, Wu T, Yeh T, Lee W, Lin Y, Hsieh T, Lin C, Yeh C, Chen T. Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas: Epidermal growth factor receptor in hepatomas. J Gastroenterol Hepatol 2015;30:1397-404. [DOI: 10.1111/jgh.12944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
2 Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018;94:329-39. [PMID: 29719302 DOI: 10.1159/000485384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Chang L, Wang G, Jia T, Zhang L, Li Y, Han Y, Zhang K, Lin G, Zhang R, Li J. Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget. 2016;7:23988-24004. [PMID: 26992211 DOI: 10.18632/oncotarget.8115] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]